Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Intellia Thera CS (NTLA)

Intellia Thera CS (NTLA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,666,024
  • Shares Outstanding, K 75,854
  • Annual Sales, $ 33,050 K
  • Annual Income, $ -267,890 K
  • 60-Month Beta 2.14
  • Price/Sales 105.47
  • Price/Cash Flow N/A
  • Price/Book 3.25
Trade NTLA with:

Options Overview Details

View History
  • Implied Volatility 102.84% ( -0.89%)
  • Historical Volatility 95.29%
  • IV Percentile 85%
  • IV Rank 55.77%
  • IV High 135.80% on 06/22/21
  • IV Low 61.29% on 11/12/21
  • Put/Call Vol Ratio 2.28
  • Today's Volume 197
  • Volume Avg (30-Day) 408
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 15,261
  • Open Int (30-Day) 12,841

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -1.30
  • Number of Estimates 12
  • High Estimate -0.98
  • Low Estimate -2.07
  • Prior Year -1.01
  • Growth Rate Est. (year over year) -28.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
38.85 +20.82%
on 05/12/22
58.77 -20.13%
on 04/19/22
-9.68 (-17.10%)
since 04/18/22
3-Month
38.85 +20.82%
on 05/12/22
103.06 -54.45%
on 02/28/22
-39.58 (-45.75%)
since 02/18/22
52-Week
38.85 +20.82%
on 05/12/22
202.73 -76.85%
on 06/30/21
-19.42 (-29.26%)
since 05/18/21

Most Recent Stories

More News
5 Cathie Wood Stocks That Remain Overvalued Despite the Market Correction

Cathie Wood stocks have been foundering for the past few months owing to volatile market conditions caused in-part by aggressive Federal Reserve interest rate hikes. So, given their companies’ bleak...

NTLA : 46.94 (-2.88%)
PATH : 16.54 (-3.05%)
ROKU : 94.84 (-2.89%)
SHOP : 360.62 (-3.23%)
TDOC : 30.87 (-6.03%)
Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat

Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.

REGN : 659.20 (-1.25%)
ALKS : 28.87 (-2.76%)
FOLD : 7.27 (-6.07%)
NTLA : 46.94 (-2.88%)
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -76.58% and 8.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?...

NTLA : 46.94 (-2.88%)
ANIP : 29.18 (-1.85%)
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress

Presented updated interim data from ongoing Phase 1 study in patients with transthyretin (ATTR) amyloidosis with polyneuropathy, demonstrating a single...

NTLA : 46.94 (-2.88%)
Drug/Biotech Stocks Q1 Earnings Due on May 5: VRTX, ZTS & More

Let's look at the five biotech/drug companies, slated to release quarterly results on May 5.

ENDP : 0.6200 (-46.55%)
VRTX : 252.35 (-3.62%)
ZTS : 158.86 (-4.55%)
NTLA : 46.94 (-2.88%)
VIR : 22.71 (-1.65%)
Incyte (INCY) Lags Q1 Earnings and Revenue Estimates

Incyte (INCY) delivered earnings and revenue surprises of -3.51% and 4%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

INCY : 73.39 (-2.81%)
NTLA : 46.94 (-2.88%)
Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing...

NTLA : 46.94 (-2.88%)
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference

Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading T cells and deployable for TCR-T and CAR-T cell...

NTLA : 46.94 (-2.88%)
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company Updates

CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused...

NTLA : 46.94 (-2.88%)
5 Beaten-Down Biotech Stocks Cathie Wood Loves

Renowned investor Cathie Wood of ARK Invest is known for her eye for stocks with enormous upside potential. Despite recent macro headwinds, the biotech industry is expected to grow tremendously in 2022,...

BEAM : 32.03 (-5.99%)
CRSP : 54.76 (+0.74%)
DNA : 2.43 (-11.31%)
FATE : 21.83 (-8.01%)
NTLA : 46.94 (-2.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Intellia Therapeutics is a leading clinical-stage genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is pursuing two primary approaches to fully realize the transformative potential of CRISPR/Cas9 in vivo programs that use intravenously administered CRISPR as the...

See More

Key Turning Points

3rd Resistance Point 52.31
2nd Resistance Point 50.70
1st Resistance Point 48.82
Last Price 46.94
1st Support Level 45.33
2nd Support Level 43.72
3rd Support Level 41.84

See More

52-Week High 202.73
Fibonacci 61.8% 140.13
Fibonacci 50% 120.79
Fibonacci 38.2% 101.45
Last Price 46.94
52-Week Low 38.85

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar